SL Science Holding Limited

About SL Science Holding Limited

SL Science Holding Limited (Nasdaq: SLBT) develops γδ T cell and Armed-T immunotherapies aimed at standardized, scalable cancer treatment. The company describes its GDT platform as applying industrial-scale logic to cell therapy so treatments can be reproducible and delivered at global scale. In addition to immune-cell programs in preclinical development, it maintains a regenerative medicine and oncology portfolio, including a non-human exosome formulation initiative using plant- and milk-derived sources. Its work focuses on translational immunology and early-stage regenerative science across oncology and related research applications.